Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2024-10-31 Report Publication Anno…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
NANOBIOTIX participera à plusieurs conférences investisseurs en novembre
Report Publication Announcement Classification · 99% confidence The document is a press release (Communiqué de Presse) dated October 31, 2024, announcing that Nanobiotix will participate in several upcoming investor conferences in November (Guggenheim, Stifel, Jefferies). It details the dates, times, locations, and participating executives for these events, and provides webcast links. This type of announcement, informing investors about management's schedule for meeting with analysts and investors, is best classified as an Investor Presentation (IP) announcement or related activity, but since it is not the presentation itself, and it is a specific announcement about management's schedule, it aligns closely with Investor Presentation (IP) materials or, more broadly, an announcement about investor engagement. However, looking at the definitions, it is not a formal regulatory filing (like 10-K or ER), nor is it a transcript (CT) or a formal dividend notice (DIV). It is an announcement detailing management's planned participation in investor-facing events. This fits best under Investor Presentation (IP) as it relates directly to investor outreach and presentation schedules, or potentially Regulatory Filings (RNS) as a general announcement. Given the specific nature of announcing participation in investor conferences where presentations/fireside chats occur, 'Investor Presentation' (IP) is the most relevant category for the *topic*, even if this specific document is the announcement *of* the participation. Since there is no specific code for 'Investor Conference Schedule Announcement', and it is not a formal report, I will check the closest fit. It is not a Report Publication Announcement (RPA) because it's not announcing the publication of a financial report. It is an announcement about management's schedule for investor engagement. In many databases, such announcements are grouped with Investor Presentations (IP) or general Investor Relations materials. Given the options, IP is the strongest thematic fit related to investor engagement schedules.
2024-10-31 French
NANOBIOTIX to Participate in Multiple Investor Conferences in November
Report Publication Announcement Classification · 99% confidence The document is a press release dated October 31, 2024, announcing that Nanobiotix management will participate in several upcoming investor conferences in November (Guggenheim, Stifel, Jefferies). This type of announcement, detailing management's schedule for engaging with investors at external events, does not fit the definitions for formal financial reports (10-K, IR, ER, MRQ), corporate governance documents (CGR, DEF 14A), or specific transactional filings (DIV, SHA, POS). It is an announcement related to investor relations activities. Since there is no specific category for 'Investor Conference Participation Announcement,' and it is a general corporate update intended for investors, the most appropriate fallback category is 'Regulatory Filings' (RNS), as it serves as a general regulatory disclosure/investor communication that doesn't fit the more specific categories.
2024-10-31 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French commercial code (Code de commerce) and AMF regulations (Autorité des Marchés Financiers) and provides a table detailing the total number of shares and voting rights as of September 30, 2024. This type of regular disclosure regarding the total share capital and voting rights is a specific regulatory requirement, often related to major shareholding notifications or capital structure updates, but the most precise fit among the provided codes for a routine disclosure of total share capital/voting rights is often captured under general regulatory filings or specific share/capital change notifications. Given the content focuses purely on the count of shares and voting rights, it aligns closely with notifications about the capital structure. However, since it is a mandatory monthly disclosure of the total share count, it is a specific type of regulatory update. It is not an Earnings Release (ER), Interim Report (IR), or a Director's Dealing (DIRS). It is a routine regulatory filing concerning the capital structure. While 'SHA' (Share Issue/Capital Change) might seem relevant, this is a routine monthly update, not an announcement of a specific *change* or *issue*. The closest general category for mandatory, non-financial periodic regulatory updates that don't fit elsewhere is often 'RNS' (Regulatory Filings) or sometimes 'MRQ' (Major Shareholding Notification) if thresholds were crossed, but this is a general capital count. Since it is a mandatory disclosure of the total capital structure, and it is not a specific financial report, 'RNS' (Regulatory Filings) serves as the best general fit for this type of routine regulatory disclosure not covered by other specific codes like 10-K or ER. However, upon reviewing the definitions, 'MRQ' (Major Shareholding Notification) is often used for filings related to changes in ownership thresholds, which is closely related to the total share count disclosure. Given the French context and the focus on total voting rights and shares, this is a standard disclosure often mandated alongside major shareholding reports. Since it is a mandatory disclosure of the total capital structure, and it is not a specific financial report, 'RNS' is the most appropriate fallback for a routine regulatory filing that doesn't fit the other specific categories like DIV, ER, or 10-K. I will classify it as RNS as it is a general regulatory announcement regarding the capital structure.
2024-10-11 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY" and explicitly references French Commercial Code articles (L.233-8 II) and the French Financial Markets Authority (AMF) regulations regarding the publication of the total number of voting rights and shares outstanding. It provides a table detailing the number of shares and voting rights as of September 30, 2024. This type of periodic disclosure regarding the capital structure and voting rights is a specific regulatory requirement, often related to major shareholding notifications or general capital updates. Since it is a direct announcement of the current share capital and voting rights count, it fits best under Major Shareholding Notification (MRQ) or potentially a general Regulatory Filing (RNS). Given the specific focus on the total number of shares and voting rights, which is a key component of major shareholding disclosures, MRQ is a strong candidate. However, the definition for MRQ is 'Notification of changes in significant share ownership levels (crossing thresholds)'. While this document provides the base figures, it is a mandatory monthly publication of the total capital, which is often filed alongside or as part of broader capital structure updates. Since it is a direct, mandatory disclosure of the capital base, and not explicitly a change in a major shareholder's stake, it is a specific type of regulatory update. Comparing the options, it is not an ER, IR, 10-K, or CT. It is a direct regulatory disclosure about the capital base. Given the options, and the fact that it is a mandatory disclosure of the capital base figures, it aligns closely with the information required for major shareholding notifications (MRQ) or a general regulatory filing (RNS). Because it is a specific, recurring regulatory disclosure about the capital base, and not a change in a specific shareholder's stake crossing a threshold, RNS (General regulatory announcements and fallback) is the most appropriate general classification if MRQ is strictly interpreted as only threshold crossings. However, in many contexts, the monthly capital base disclosure is grouped with shareholding reports. Let's re-evaluate the definitions. It is not a DVA (voting results), nor a SHA (new share issue). It is a statement of the current capital base. This is a very specific regulatory filing. Since it is a mandatory disclosure of the total capital base, and not a change in a specific shareholder's stake, RNS is the safest fallback for a specific regulatory notice that doesn't fit perfectly elsewhere, although it is highly related to MRQ. Given the context of French regulation, this is a standard 'information relative au nombre total d'actions et de droits de vote'. I will classify it as RNS as it is a general regulatory announcement that doesn't fit the other specific categories like DIV, CAP, or SHA, and MRQ is defined narrowly as crossing thresholds.
2024-10-11 English
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers pour le premier semestre 2024
Earnings Release Classification · 95% confidence The document is a press release from Nanobiotix titled 'NANOBIOTIX FAIT LE POINT SUR SES ACTIVITÉS ET PUBLIE SES RÉSULTATS FINANCIERS POUR LE PREMIER SEMESTRE 2024'. It provides a summary of financial results, operational highlights, and clinical trial updates for the first half of 2024. While it mentions that the full financial report has been filed with the AMF, the document itself serves as the initial announcement of these results (Earnings Release). It contains key financial metrics (revenue, R&D expenses, net loss, cash position) and business updates, fitting the definition of an Earnings Release (ER). H1 2024
2024-09-18 French
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
Earnings Release Classification · 100% confidence The document is explicitly titled as a "*PRESS RELEASE*" and its primary purpose is to announce two things: a "BUSINESS UPDATE" and the reporting of "HALF YEAR 2024 FINANCIAL RESULTS". It contains key financial figures for the six-month period ended June 30, 2024 (Revenue, R&D Expenses, Net Loss, Cash position), which strongly suggests a periodic financial report summary. However, the document also contains a specific section titled "Availability of the Half Year 2024 Financial Reports" which states: "The 2024 half-year financial report has been filed with the French financial market authority (Autorité des marchés financiers). It is available to the public on the Company's website...". This structure—a press release summarizing results and pointing to the full, filed report—is characteristic of an Earnings Release (ER) or a Report Publication Announcement (RPA). Since it contains the actual summarized financial results and operational highlights, it functions as the initial announcement of those results, making 'Earnings Release' (ER) the most appropriate classification over a simple RPA. It is not the comprehensive 'Interim / Quarterly Report' (IR) itself, as it directs the reader to the filed report. H1 2024
2024-09-18 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.